11c-bms-986196

11c-bms-986196 is a radiolabeled investigational drug developed as a positron emission tomography (PET) ligand for imaging and research purposes in the context of multiple sclerosis (MS). The non-radioactive version, BMS-986196, is an oral central nervous system (CNS)-penetrant Bruton’s tyrosine kinase (BTK) inhibitor. BTK inhibitors are being explored for their potential to modulate immune cell activity implicated in MS pathogenesis. The compound has been studied primarily to evaluate its safety, tolerability, pharmacokinetics, biodistribution, and CNS signal after intravenous administration in both healthy volunteers and patients with multiple sclerosis[1][2][5][6]. It is not approved for clinical use but has completed Phase 1 trials.